Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Chames

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Molecular Biosystems|September 23, 2010
Strong and oriented immobilization of single domain antibodies from crude bacterial lysates for high-throughput compatible cost-effective antibody array generationKlervi Even-Desrumeaux, Daniel Baty, Patrick Chames
Cancers|November 12, 2013
State of the art in tumor antigen and biomarker discoveryKlervi Even-Desrumeaux, Daniel Baty, Patrick Chames
Thescientificworldjournal|June 22, 2010
Therapeutic antibodies for the treatment of pancreatic cancerPatrick Chames, Brigitte Kerfelec, Daniel Baty
Molecular Therapy. Oncology|April 17, 2026
Mesothelin biology and the evolving landscape of targeted immunotherapyRemy Boisgard, Patrick Chames, Brigitte Kerfelec
Methods in Molecular Biology (Clifton, N.J.)|April 24, 2002
Selection of antibodies against biotinylated antigensPatrick Chames, Hennie R Hoogenboom, Paula Henderikx
Lab on a Chip|May 8, 2024
Antigen density and applied force control enrichment of nanobody-expressing yeast cells in microfluidicsMerlin Sanicas, Rémy Torro, Laurent Limozin, et al.
Biomaterials|November 29, 2025
Functional targeting of Glypican-4 by a conformation-specific single-domain antibodyRemi Bonjean, Rossana Cuciniello, Brigitte Kerfelec, et al.
British Journal of Pharmacology|May 23, 2009
Therapeutic antibodies: successes, limitations and hopes for the futurePatrick Chames, Marc Van Regenmortel, Etienne Weiss, et al.
Antibodies (Basel, Switzerland)|September 28, 2019
Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?Joanie Del Bano, Patrick Chames, Daniel Baty, et al.
Oncotarget|July 1, 2014
A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapyMarc Turini, Patrick Chames, Pierre Bruhns, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Molecular Biosystems|September 23, 2010
Strong and oriented immobilization of single domain antibodies from crude bacterial lysates for high-throughput compatible cost-effective antibody array generationKlervi Even-Desrumeaux, Daniel Baty, Patrick Chames
Cancers|November 12, 2013
State of the art in tumor antigen and biomarker discoveryKlervi Even-Desrumeaux, Daniel Baty, Patrick Chames
Thescientificworldjournal|June 22, 2010
Therapeutic antibodies for the treatment of pancreatic cancerPatrick Chames, Brigitte Kerfelec, Daniel Baty
Molecular Therapy. Oncology|April 17, 2026
Mesothelin biology and the evolving landscape of targeted immunotherapyRemy Boisgard, Patrick Chames, Brigitte Kerfelec
Methods in Molecular Biology (Clifton, N.J.)|April 24, 2002
Selection of antibodies against biotinylated antigensPatrick Chames, Hennie R Hoogenboom, Paula Henderikx
Lab on a Chip|May 8, 2024
Antigen density and applied force control enrichment of nanobody-expressing yeast cells in microfluidicsMerlin Sanicas, Rémy Torro, Laurent Limozin, et al.
Biomaterials|November 29, 2025
Functional targeting of Glypican-4 by a conformation-specific single-domain antibodyRemi Bonjean, Rossana Cuciniello, Brigitte Kerfelec, et al.
British Journal of Pharmacology|May 23, 2009
Therapeutic antibodies: successes, limitations and hopes for the futurePatrick Chames, Marc Van Regenmortel, Etienne Weiss, et al.
Antibodies (Basel, Switzerland)|September 28, 2019
Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?Joanie Del Bano, Patrick Chames, Daniel Baty, et al.
Oncotarget|July 1, 2014
A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapyMarc Turini, Patrick Chames, Pierre Bruhns, et al.
Pageof 9